The results indicated that treatment with the SREBP1 inhibitor cinobufotalin or the ACLY inhibitor NDI‐091143 effectively diminished the enhancement of the proliferation and invasion capabilities induced by the overexpression of EN2 in GBM cells (Figures 5F,G and S2G,H). The gene discussed is SREBF1; the disease is glioblastoma.